PCRRT Multi-Center Registry Data Effective April 1, 2002 Multi-Center Pediatric CRRT Registry Stuart L. Goldstein, MD Assistant Professor of Pediatrics.

Slides:



Advertisements
Similar presentations
Timothy E. Bunchman Professor Pediatrics
Advertisements

AKI in Pediatrics Patrick D. Brophy MD Associate Professor
Renal Replacement Therapy Options for Children
Acute Renal Replacement Therapy for the Infant Dr.Fahad Gadi, MD Pediatrics Demonstrator King Abdulaziz University Rabigh Medical School.
Acute Renal Replacement Therapy for the Infant Dr.Fahad Gadi, MD Pediatrics Demonstrator King Abdulaziz University Rabigh Medical School.
Pediatric CRRT: Terminology and Physiology
CVVH vs CVVHD Does it Matter?
MANAGEMENT OF CONTINUOUS HEMODIALYSIS
Continuous Renal Replacement Therapy. Why continuous Therapies? Continuous therapies closely mimic the GFR of native kidneys Large amounts of fluid.
ECMO in CRRT – What are the Data?
Pediatric Bone Marrow Transplant Recipients with Acute Kidney Injury Stuart L. Goldstein, MD Associate Professor of Pediatrics Baylor College of Medicine.
Dialysis and Replacement Solutions for CRRT
Pediatric Bone Marrow Transplant Recipients with Acute Renal Failure Stuart L. Goldstein, MD Assistant Professor of Pediatrics Baylor College of Medicine.
Pediatric Acute Renal Failure: CRRT/Dialysis Outcome Studies Stuart L. Goldstein, MD Assistant Professor of Pediatrics Baylor College of Medicine.
Pediatric CRRT: The Prescription
Acute Renal Replacement Therapy for the Infant Jordan M. Symons, MD University of Washington School of Medicine Children’s Hospital & Regional Medical.
Dialysis and Replacement Solutions for Pediatric CRRT
Visit the Exhibitors!!! They are around the corner in room Coronado A-C Represented there are Dialysis Equipment Companies Solution Companies Access Companies.
Hemodynamic changes during hemofiltration in meningococcal septicemia Dr Rajiv Chhabra Dr Prabhat Maheshwari Dr Claudine De Munter.
Pediatric CRRT: The Prescription Stuart L. Goldstein, MD Associate Professor of Pediatrics Baylor College of Medicine.
What form of anticoagulation is the “best” Or why is Citrate better then Heparin or Prostacyclin.
The Prospective Pediatric CRRT (ppCRRT) Registry Stuart L. Goldstein, MD Principal Investigator and Founder Timothy E Bunchman Helen DeVos Children’s Hospital.
Practical Considerations for CRRT Helen Currier RN, BSN, CNN Nancy McAfee RN, BSN, CNN.
A Retrospective Study of Outcomes in Pediatric Hematology/Oncology Patients Receiving Continuous Venovenous Hemodialysis Y Avent 1, N Henderson 1, T Collie.
Sean M Bagshaw, MD, MSc Division of Critical Care Medicine Faculty of Medicine and Dentistry, University of Alberta 1 st International Symposium on AKI.
Anticoagulation in CRRT
PCRRT PRESCRIPTIONS in ARF Patrick D. Brophy MD University of Michigan Pediatric Nephrology.
Stuart L. Goldstein, MD Professor of Pediatrics
Tomáš Zaoral1, Michal Hladík1, Jana Zapletalová2 1Pediatric intensive care unit, Department of Pediatrics,Faculty of Medicine, University Hospital Ostrava.
Acute kidney injury and fluid overload during pediatric extracorporeal membrane oxygenation are associated with increased mortality: a report of the multi-centre.
Use of CRRT in ECMO: Is It Valuable? James D. Fortenberry MD, FCCM, FAAP Associate Professor of Pediatrics Emory University School of Medicine Director,
Excessive fluid is not needed: So why is Dr. Durward so wasteful? Timothy E Bunchman MD Professor & Director Pediatric Nephrology
DIALYSIS SOLUTIONS INC.
Common Prescription Errors in Pediatric CRRT: a “Top 10 List” Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital.
THE EFFECT OF TIMING OF INITITIATION OF CRRT ON PATIENTS REQUIRING EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) Asif Mansuri, MD, MRCPI Fellow, Division.
University of Pittsburgh
David Askenazi MD, MSPH Associate Professor of Pediatrics 2Smaller Circuits for Smaller Patients Improving Renal Support with Aquadex™ Machine.
Brophy University of Iowa Pediatric CRRT Anticoagulation Patrick Brophy MD Director Pediatric Nephrology University of Iowa- Children’s Hospital PCRRT.
Citrate Anticoagulation
Common Terminology Used and Physiology in CRRT Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital Seattle, WA.
Results Methods Abstract Number 69 Objectives 1.Nephrol Dial Transplant (2011) 26: 537–543 2.J Support Oncol 2011;9:149–155 3.N Engl J Med. 2009; 361:1627–1638.
Dosing of Anti-Fungal agents on CRRT Timothy E. Bunchman Professor and Director Pediatric Nephrology & Transplantation Children’s Hospital of Richmond.
PCRRT Tûr'mə-nŏl'ə-jē Helen Currier BSN, RN, CNN Assistant Director, Renal/Pheresis Texas Children’s Hospital Houston, Texas.
Cytokine and Soluble Fas Ligand Response in Children with Septic Acute Renal Failure (ARF) on CVVH Paden ML, Fortenberry JD, Rigby MR, Trexler AM, Heard.
Continuous Renal Replacement Therapy Developed by: Critical Care and Hemodialysis Educators, February 2009 King Faisal Specialist Hospital and Research.
Convection (CVVH) is Better! Timothy E Bunchman MD Professor & Director Pediatric Nephrology
Use of CRRT in ECMO: Is It Valuable? James D. Fortenberry MD, FCCM, FAAP Associate Professor of Pediatrics Emory University School of Medicine Director,
Renal Replacement Therapy in the CICU Stuart L. Goldstein, MD Professor of Pediatrics University or Cincinnati College of Medicine Director, Center for.
CONTINUOUS RENAL REPLACEMENT THERAPY
CRRT Fundamentals Pre- and Post- Test
University of Alabama at Birmingham
CRRT (Continuous Renal Replacement Therapy)
When fluids go wrong: CRRT in fluid overload
Quantification and Dosing of Renal Replacement Therapy in Acute Kidney Injury: A Reappraisal Blood Purif 2017;44: DOI: / Fig.
Improving outcomes in AKI and CRRT: Does Quality matter?
Devices use for Neonatal AKI
Prescriptions in CRRT Timothy E Bunchman MD Professor & Director
Vascular Access and Infused Fluids for Pediatric CRRT
DEBATE: Timing of CRRT in Critical Care
OUTCOMES OF REGIONAL CITRATE ANTICOAGULATION (RCA) IN PEDIARTIC CONTINUOUS RENAL REPLACEMENT THERAPY (pCRRT) IN A SINGLE CENTER Issa Alhamoud, Diane Gollhofer,
Objectives Early initiation of continuous renal replacement therapy
T.Zaoral,M.Hladík, M.Sádlo, V.Vobruba
Unique Considerations in Renal Replacement Therapy in Children: Core Curriculum 2014  Sidharth Kumar Sethi, MD, Timothy Bunchman, MD, Rupesh Raina, MD,
Andrew Durward St Thomas NHS Foundation Trust Orlando 2017 CRRT IN AKI.
Pediatric CRRT Terminology
Basics of CRRT: Terminology
J Foland, J Fortenberry, B Warshaw,
SCUF Slow Continuous Ultrafiltration
Children’s Memorial Hospital Northwestern University
Case 20 kg child with sepsis and oliguria on norepinephrine with a BP of 95/45 Vent at 70% FIO2 and a PEEP of 8 FO at 15% K of 6 meq/dl and a BUN of 100.
Presentation transcript:

pCRRT Multi-Center Registry Data Effective April 1, 2002 Multi-Center Pediatric CRRT Registry Stuart L. Goldstein, MD Assistant Professor of Pediatrics Baylor College of Medicine

pCRRT Multi-Center Registry Data Effective April 1, 2002 Overview Registry study phases –Study design –Study aims Current participating centers –Institutional practice protocol variation Current data analysis

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry: Phase 1 Design Collect prospective data from 5 to 10 pediatric centers treating 15 to 20 patients annually ( patients over 3 years) Each center follows own institutional practice –Patient selection –Initiation and termination –Anti-coagulation protocols –Convection versus diffusion versus hemodiafiltration –Fluid composition Cytokine clearance study

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry: Phase 1 Aims Assess for potential associations between various practices and pediatric patient outcomes Assess for potential associations between varying practices and CRRT machine functioning Determine CRRT clearance rates of various SIRS and CARS cytokines in children with sepsis

pCRRT Multi-Center Registry Data Effective April 1, 2002 Current Registry Centers and PI Texas Children’s Hospital (January 2001) Boston Children’s Hospital (March 2001) Seattle Children’s Hospital (July 2001) Univ of Alabama Children’s (July 2001) Univ of Michigan (December 2002) Stuart Goldstein, MD Michael Somers, MD Jordan Symons, MD Timothy Bunchman, MD Patrick Brophy, MD Melissa Gregory, MD

pCRRT Multi-Center Registry Data Effective April 1, 2002 Pre-CRRT Registry Data Demographics –Primary disease, co-morbid illness, age, gender, days in PICU CRRT specifics –Treatment or prevention of fluid overload and/or electrolyte imbalance –Access size and site Renal failure indices –GFR (Schwartz) –Percent fluid overload (%FO) –Urine output in previous 24 hours

pCRRT Multi-Center Registry Data Effective April 1, 2002 Registry PICU Data PRISM 2 at ICU admission and CRRT initiation CRRT initiation –CVP –MAP –Pressor number and specific drugs –Diuretic use CRRT course –Maximum pressor number –MAP change –Pressors weaned?

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry Circuit Data Separate data page for each circuit Machine brand Extracorporeal volume Priming fluid –NS –albumin –blood mixed with FFP, albumin, or bicarbonate Dialysis or replacement fluid composition –Normocarb™ (Dialysis Solutions, Inc) –Baxter hemofiltration fluid™ –Saline, Ringer’s lactate, peritoneal dialysis fluid

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry Circuit Data Anticoagulation –Citrate –Heparin rate ACT measured per hour Mean ACT # ACT < 180 seconds Clearance prescription –CVVH versus CVVHD versus CVVHDF –ml/1.73m 2 /hour Nutrition prescription –Kcal/kg/day –Grams protein/kg/day

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry Patient Data: Outcome Survival versus death (discharge from PICU) Attainment of target dry weight Reason to discontinue CRRT –Death –Regained renal function –Underlying illness resolved –Tolerates intermittent hemodialysis

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry Circuit Data: Outcome Filter life-span (hours) Reason for circuit change –clotting –access malfunction –machine malfunction –unrelated patient indication (e.g., needs CT scan) –CRRT discontinued

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry: Results (4/1/2002) 42 patients entered into study 36 with complete data 128 circuits 4905 cumulative treatment hours –Mean hours –Range 1 to 118 hours

pCRRT Multi-Center Registry Data Effective April 1, 2002 Baseline Demographics

pCRRT Multi-Center Registry Data Effective April 1, 2002 Registry Center Census

pCRRT Multi-Center Registry Data Effective April 1, 2002 Primary Disease

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry Modality

pCRRT Multi-Center Registry Data Effective April 1, 2002 Reason to Start CRRT

pCRRT Multi-Center Registry Data Effective April 1, 2002 Outcome

pCRRT Multi-Center Registry Data Effective April 1, 2002 Clinical Variables and Outcome Survival not associated with –GFR –Pressor number –MAP –PRISM at ICU admission –Age –Weight Survival associated with –PRISM at CRRT initiation –% Fluid overload at CRRT initiation

pCRRT Multi-Center Registry Data Effective April 1, 2002 PRISM at CRRT Initiation and Outcome P <

pCRRT Multi-Center Registry Data Effective April 1, 2002 Fluid Overload and Outcome P < 0.05

pCRRT Multi-Center Registry Data Effective April 1, 2002 Fluid Overload and Outcome: Renal Failure Only P < 0.05

pCRRT Multi-Center Registry Data Effective April 1, 2002 Fluid Overload, Severity of Illness and Outcome Greater degrees of fluid overload associated with death, even when controlled for severity of illness by PRISM score (multiple regression analysis; p<0.03)

pCRRT Multi-Center Registry Data Effective April 1, 2002 Circuit Change Reason

pCRRT Multi-Center Registry Data Effective April 1, 2002 Anticoagulation Method and Circuit Life P < N=69 N=38

pCRRT Multi-Center Registry Data Effective April 1, 2002 pCRRT Registry Future Phases Assess association between nutrition and outcome Assess cytokine levels and clearance Test new products devices safely and efficiently Prospective randomized trials –Dose –Fluid options –Selective cytokine removal –Time to intervention –Disease-specific protocol and outcome Web-based for easy access and query